FDA Approves Second HIV Prevention Treatment

FDA Approves Second
HIV Prevention Treatment.
The pre-exposure
prophylaxis (PrEP) is
called Descovy. It was
developed by Gilead Sciences.
As a PrEP drug,
Descovy is meant
to be taken daily.
PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent
HIV infection, Jeffrey Murray, M.D. FDA, via CNBC.
Combined with safe-sex practices,
Descovy is recommended by the
FDA as a component of a broad
strategy to prevent new HIV infections.
Close to 40,000 people in the
U.S. were diagnosed with HIV in 2017.
The FDA aims
to reduce new HIV
infections by 90% by 2030